

March 15, 2014

To,

- 1) **BSE Limited**
Corporate Relationship Dept., 1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001
- 2) **National Stock Exchange of India Limited**
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051
- 3) **Bangalore Stock Exchange Limited**
Stock Exchange Tower
51, 1st Cross, J.C. Road
Bangalore – 560027

Dear Sir,

Sub: Intimation under Clause 36 of the Listing Agreement re proposal by AstraZeneca Pharmaceuticals AB for voluntary delisting offer.

Ref: Scrip Code – BgSE: ASTRAZEN, BSE: 506820, NSE: ASTRAZEN

We refer to our letter dated March 13, 2014 on the captioned subject.

Pursuant to and in accordance with Regulation 8(1)(a) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, the delisting proposal received from AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company, vide their letter dated March 1, 2014, a copy of which was forwarded to you with our letter dated March 1, 2014, was considered and approved by the Board of the Company at its meeting held on March 15, 2014.

This is for your information and record.

Thanking You

For **AstraZeneca Pharma India Limited**


Pawan Singhal
VP – Legal & Company Secretary